ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1793

The Cyclooxygenase/Prostaglandin-E2 Pathway Is Critical for Autocrine IL-17A Production by Th17 Cells Upon Synovial Fibroblast Interaction

Sandra M.J. Paulissen1, Jan Piet van Hamburg2, Nadine Davelaar3, Patrick S. Asmawidjaja3, Johanna M.W. Hazes4 and Erik Lubberts3, 1Immunology, Erasmus Medical Center, Immunology, Rotterdam, Netherlands, 2Rheumatology, Erasmus MC, Rotterdam, Netherlands, 3Rheumatology, Erasmus MC, University Medical Center, Rotterdam, Netherlands, 4Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: cytokines, Fibroblasts, prostaglandins and rheumatoid arthritis (RA), T cells

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Cytokines, Mediators, and Gene Regulation

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Recently, we have shown that Th17, but not Th1 cells, from patients with early rheumatoid arthritis (RA) are potent activators of RA synovial fibroblasts (RASF) resulting in autocrine IL-17A production. This IL-17A production results in a pro-inflammatory loop, which is characterized by an up-regulation in pro-inflammatory cytokines and cartilage degrading enzymes. The autocrine IL-17A production by Th17 cells is critical for the perseverance of the pro-inflammatory loop, but the mechanism underlying the autocrine IL-17A induction is unclear. The objective of this study is to investigate the mechanism responsible for the autocrine IL-17A induction upon Th17-RASF interaction.

Methods:

CD4+CD45RO+CCR6+ (Th17) and CD4+CD45RO+CCR6- (Th1) cells were isolated by fluorescence-activated cell sorting (FACS) sorting from healthy controls and early RA patients. These cells were co-cultured with RASF, in the presence of neutralizing antibodies directed against soluble IL-6R (anti-sIL-6R) and/or IL-1β, and celecoxib. Gene expression profiles were generated and supernatant was collected for cytokine analyses by enzyme-linked immunosorbent assay (ELISA).

Results:

Gene expression analyses revealed that the genes encoding for IL-6 and IL-1β were up-regulated in Th17-RASF cultures. These data were confirmed by ELISA and quantitative polymerase chain reaction (Q-PCR), respectively. Since IL-1β and IL-6 may be involved in IL-17/Th17 polarization we examined the contribution of these cytokines on the autocrine IL-17A loop. Blockade of IL-1β and IL-6 significantly suppressed IL-17 production. However the effects of IL-1β and IL-6 blockade were limited, indicating the requirement of an additional mechanism.

Interestingly, the genes encoding for cyclo-oxygenase-2 (COX-2) and prostaglandin-E-synthase (PTGES), which are involved in prostaglandin-E2 (PGE2) synthesis, were also up-regulated in Th17-RASF cultures. This was associated with a dramatic increase of PGE2 production in Th17-RASF cultures compared to Th1-RASF cultures. Treatment of Th17-RASF cultures with celecoxib, a COX-2 inhibiter, resulted in significant and specific inhibition of the fraction of IL-17A producing cells and the IL-17A levels. No inhibitory effects were found on IFN-γ and TNF-α production. Moreover, celecoxib treatment functionally inhibited the pro-inflammatory loop as production of the pro-inflammatory mediators IL-6 and IL-8 and tissue destructive enzymes MMP-1 and MMP-3 were significantly suppressed.

Conclusion:

These findings show the critical role of the COX/PGE2 pathway in the autocrine IL-17A production upon Th17 and synovial fibroblast interaction. Inhibition of this pathway down-regulates the pro-inflammatory feedback loop induced by Th17-RASF interaction leading to less production of pro-inflammatory cytokines and destructive mediators.


Disclosure:

S. M. J. Paulissen,
None;

J. P. van Hamburg,
None;

N. Davelaar,
None;

P. S. Asmawidjaja,
None;

J. M. W. Hazes,
None;

E. Lubberts,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-cyclooxygenaseprostaglandin-e2-pathway-is-critical-for-autocrine-il-17a-production-by-th17-cells-upon-synovial-fibroblast-interaction/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology